Literature DB >> 18172654

sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis.

Gert E Hein1, Marit Meister, Peter Oelzner, Sybille Franke.   

Abstract

The aim of this study was to investigate sRANKL and OPG levels in serum and synovial fluid (SF) and to evaluate their relations in patients with RA in comparison to those with non-erosive arthritis (NEA). The study included 45 unselected RA patients with knee joint effusions and 27 patients with knee joint effusions because of NEA. Serum and SF samples were investigated isochronously. OPG and sRANKL were measured by ELISA assays. In RA, sRANKL levels were higher in serum than in SF (P = 0.007). In contrast, the NEA revealed higher sRANKL in SF compared to the serum (P = 0.001). Though in RA the average levels of sRANKL(ser) were 5.6 times and of sRANKL(syn) 1.5 times higher than in NEA, the differences were not significant. The free (unbound) OPG in SF was not significantly different in RA compared to NEA. Also in serum, the measured free OPG was only slightly higher in RA. There were no significant differences between RA and NEA concerning ESR and CRP. Significant correlations could be found between sRANKL(syn )and CRP (r = 0.453; P = 0.005) as well as ESR (r = 0.362; P = 0.033) in RA. Nearly a positive correlation was evident also between sRANKL(syn) and CRP in NEA (r = 0.520; P = 0.08). RA and NEA differ in particular concerning their power and intensity to destruct the juxtaarticular bone. This is the most remarkable finding of this study, that in RA a high part of sRANKL seems to be OPG bound and cleared by the blood stream, but the sRANKL neutralizing capacity of produced OPG in opposite to NEA is not sufficient to prevent osteoclast activation and bone destruction in the RA joint.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18172654     DOI: 10.1007/s00296-007-0514-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  19 in total

1.  Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival.

Authors:  L Lum; B R Wong; R Josien; J D Becherer; H Erdjument-Bromage; J Schlöndorff; P Tempst; Y Choi; C P Blobel
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

2.  Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.

Authors:  S Kotake; N Udagawa; M Hakoda; M Mogi; K Yano; E Tsuda; K Takahashi; T Furuya; S Ishiyama; K J Kim; S Saito; T Nishikawa; N Takahashi; A Togari; T Tomatsu; T Suda; N Kamatani
Journal:  Arthritis Rheum       Date:  2001-05

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.

Authors:  J E Fata; Y Y Kong; J Li; T Sasaki; J Irie-Sasaki; R A Moorehead; R Elliott; S Scully; E B Voura; D L Lacey; W J Boyle; R Khokha; J M Penninger
Journal:  Cell       Date:  2000-09-29       Impact factor: 41.582

5.  Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes.

Authors:  María-Eugenia Miranda-Carús; Marta Benito-Miguel; Alejandro Balsa; Tatiana Cobo-Ibáñez; Carlos Pérez de Ayala; Dora Pascual-Salcedo; Emilio Martín-Mola
Journal:  Arthritis Rheum       Date:  2006-04

6.  Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent.

Authors:  I Itonaga; Y Fujikawa; A Sabokbar; D W Murray; N A Athanasou
Journal:  J Pathol       Date:  2000-09       Impact factor: 7.996

7.  Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis.

Authors:  T N Crotti; M D Smith; H Weedon; M J Ahern; D M Findlay; M Kraan; P P Tak; D R Haynes
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

8.  RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.

Authors:  A R Pettit; N C Walsh; C Manning; S R Goldring; E M Gravallese
Journal:  Rheumatology (Oxford)       Date:  2006-02-20       Impact factor: 7.580

9.  Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls.

Authors:  D R Haynes; E Barg; T N Crotti; C Holding; H Weedon; G J Atkins; A Zannetino; M J Ahern; M Coleman; P J Roberts-Thomson; M Kraan; P P Tak; M D Smith
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

10.  The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

Authors:  T L Burgess; Y Qian; S Kaufman; B D Ring; G Van; C Capparelli; M Kelley; H Hsu; W J Boyle; C R Dunstan; S Hu; D L Lacey
Journal:  J Cell Biol       Date:  1999-05-03       Impact factor: 10.539

View more
  6 in total

1.  A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis.

Authors:  Wenfeng Tan; Hui Wu; Jian Zhao; Lezlie A Derber; David M Lee; Nancy A Shadick; Doyt L Conn; Edwin A Smith; Vivian H Gersuk; Gerald T Nepom; Larry W Moreland; Daniel E Furst; Susan D Thompson; Beth L Jonas; V Michael Holers; David N Glass; Pojen P Chen; S Louis Bridges; Michael E Weinblatt; Harold E Paulus; Betty P Tsao
Journal:  Arthritis Rheum       Date:  2010-10

2.  A significant association exists between receptor tyrosine kinase-like orphan receptor 2 gene variants and the OPG/RANKL ratio in human plasma.

Authors:  S Ermakov; S Trofimov; I Malkin; G Livshits
Journal:  Osteoporos Int       Date:  2011-11-05       Impact factor: 4.507

3.  Dickkopf-1 as potential biomarker to evaluate bone erosion in systemic lupus erythematosus.

Authors:  Li Long; Yanying Liu; Shiyao Wang; Yi Zhao; Jianping Guo; Ping Yu; Zhanguo Li
Journal:  J Clin Immunol       Date:  2010-06-30       Impact factor: 8.317

4.  Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade.

Authors:  Terence Rooney; Carl K Edwards; Martina Gogarty; Laura Greenan; Douglas J Veale; Oliver FitzGerald; Jean-Michel Dayer; Barry Bresnihan
Journal:  Rheumatol Int       Date:  2009-10-22       Impact factor: 2.631

Review 5.  Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.

Authors:  Theodoros Kelesidis; Judith S Currier; Otto O Yang; Todd T Brown
Journal:  AIDS Rev       Date:  2014 Jul-Sep       Impact factor: 2.381

6.  Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis.

Authors:  Kristyna Brabnikova-Maresova; Katerina Jarosova; Karel Pavelka; Jan J Stepan
Journal:  Arthritis Res Ther       Date:  2014-10-04       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.